First‐line or second‐line PD‐1 inhibition in advanced oesophageal squamous cell carcinoma: A prospective, multicentre, registry study.
What is known and objective: First‐line and second‐line immunotherapy with programmed death‐1 (PD‐1) inhibitors both improve overall survival in patients with advanced oesophageal squamous cell cancer (ESCC). This study explored survival differences between first‐line and second‐line PD‐1 inhibition...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 47; no. 6; pp. 732 - 738 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jun2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |